Janssen Pharmaceuticals, Inc. announced that the FDA approved under priority review the New Drug Application (NDA) for the three-month long-acting...
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the FDA has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for PP 6M (paliperidone palmitate 6-month) for the treatment of adults diagnosed with schizophrenia.
Janssen Pharmaceuticals has announced results of its landmark PRIDE trial, a prospective, randomized clinical trial to compare Invega Sustenna/Xeplion (paliperidone...